DeAngelis D V, Woolley J L, Sigel C W
Wellcome Research Laboratories, Research Triangle Park, North Carolina 22709.
Ther Drug Monit. 1990 Jul;12(4):382-92. doi: 10.1097/00007691-199007000-00015.
Procedures for the simultaneous determination of trimethoprim (TMP) and sulfamethoxazole (SMX) in plasma or urine are reported. The drugs are extracted from plasma or urine by a single solid-phase extraction and quantitated by high-performance liquid chromatography. Both drugs are analyzed in the same chromatographic run. Intra- and interassay variability are less than 10% for both compounds, and the recovery and precision of TMP measurement are unaffected by concurrent SMX concentrations. Limits of quantitation for TMP and SMX in plasma were 0.02 and 0.21 microgram/ml, respectively. In urine, the limit of quantitation for both drugs was 1.0 microgram/ml. Metabolites of TMP and SMX did not interfere with the assay. Pharmacokinetic parameters from volunteers given two formulations of co-trimoxazole in a crossover comparison study are reported.
本文报道了同时测定血浆或尿液中甲氧苄啶（TMP）和磺胺甲恶唑（SMX）的方法。通过单次固相萃取从血浆或尿液中提取药物，并采用高效液相色谱法定量。两种药物在同一色谱运行中进行分析。两种化合物的批内和批间变异均小于10%，TMP测量的回收率和精密度不受同时存在的SMX浓度影响。血浆中TMP和SMX的定量限分别为0.02和0.21微克/毫升。在尿液中，两种药物的定量限均为1.0微克/毫升。TMP和SMX的代谢产物不干扰测定。报道了在交叉比较研究中给予志愿者两种复方新诺明制剂后的药代动力学参数。
